Cargando…
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
Dysglycaemic disease is one of the most important health issues facing the world in the 21(st )century. Patients with type 2 diabetes and individuals with prediabetes are at risk of developing macrovascular and microvascular complications. Long-term management strategies are therefore required that...
Autor principal: | Hanefeld, Markolf |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040135/ https://www.ncbi.nlm.nih.gov/pubmed/17697384 http://dx.doi.org/10.1186/1475-2840-6-20 |
Ejemplares similares
-
Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
por: Hanefeld, Markolf, et al.
Publicado: (2013) -
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials
por: Hanefeld, Markolf, et al.
Publicado: (2016) -
The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL
por: Hanefeld, Markolf, et al.
Publicado: (2017) -
A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus
por: Owens, David R., et al.
Publicado: (2017) -
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
por: Hanefeld, Markolf, et al.
Publicado: (2020)